Scottish MedTech Company Seluna Launches NHS Study to Advance Paediatric Sleep Diagnosis

Seluna, a Scottish MedTech Company developing diagnosis solutions for paediatric sleep disorders, led by Dr Scott Black, Dr Yola Jones, and others, has launched an NHS Study to advance paediatric sleep diagnosis. The validation study follows Seluna’s recent success in securing nearly £650,000 funding via continued support from existing backers, Gabriel Investment Syndicate, Scottish Enterprise, and the University of Strathclyde, as well as a new investor, STAC Invest.

Glasgow-based MedTech has begun a clinical validation study with the Royal Hospital for Children to improve the diagnosis of childhood sleep disorders. The study, running until 2025 with 500 patients, will test Seluna’s AI-powered software that automates sleep study analysis to aid doctors in diagnosing paediatric sleep apnoea. If validated, it would be the first diagnostic SaMD built specifically for paediatric sleep medicine, addressing delays caused by today’s slow, manual processes.

Seluna’s AI software automates paediatric sleep study analysis, reducing clinician workload while ensuring transparent, data-driven decisions. Beyond diagnosis, it aims to provide physiological insights to guide personalised treatment, helping avoid unnecessary surgeries and ensuring children who need intervention are properly identified.

Seluna’s multi-site NHS validation programme aims to ensure its technology serves all communities equitably. The company is targeting UK Class I medical device approval by 2026 and FDA Class II approval in the US by 2027, paving the way for broad adoption and international expansion.